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Better prognostic and predictive markers in melanoma are needed to select patients for therapy. We utilized a dual-lectin aﬃnity
chromatography and a natural protein microarray-based analysis to select a subproteome of target glycoproteins to proﬁle serum
antibodies against melanoma associated antigens that may predict nodal positivity. We identiﬁed 5 melanoma-associated antigens
using this microarray coupled to mass spectrometry; GRP75, GRP94, ASAH1, CTSD and LDHB. We evaluated their predictive
value for nodal status adjusting for age, gender, Breslow thickness, mitotic rate and ulceration using standard logistic regression.
After adjustment, ASAH1, CTSD and LDHB were signiﬁcantly negatively associated with nodal status (P = 0.0008) and GRP94
was signiﬁcantly positively associated (P = 0.014). Our best multivariate model for nodal positivity included Breslow thickness,
presence of serum anti-ASAH1, anti-LDHB or anti-CTSD, and presence of serum anti-GRP94, with an area under the ROC curve
of 0.869. If validated, these results show promise for selecting clinically node negative patients for SLN biopsy. In addition, there
is strong potential for glycoprotein microarray to screen serum autoantibodies that may identify patients at high risk of distant
metastases or those likely or unlikely to respond to treatment, and these proteins may serve as targets for intervention.
1.Introduction
The present staging system for melanoma, using Breslow
thickness, ulceration, mitotic rate, and the presence of
regional and distant metastases, stratiﬁes patients into
heterogenous groups, with wide variability in outcome or
response to therapy. This results in applying more aggressive
surgical and adjuvant therapies to large populations, diluting
the impact of therapy while exposing more patients to
toxicity. Better biomarkers in melanoma are needed to target
both surgical and adjuvant therapies, but to date have been
elusive. For many solid tumors, the large-scale analysis of
geneexpressionattheRNAlevelcanprovidepatternsofgene
expressionthatmaystratifypatientsbetterthanTNMstaging
and help guide therapy. However, this approach requires
freshtissuefromalargenumberofprimarytumors,aunique
challenge in melanoma where the primary is often only a few
millimeters in size, with no residual tissue after the diagnosis
has been made.
For this reason, we chose to examine serum protein
markers, hypothesizing that antibody discovery was ideal for
the patient with malignant melanoma, as primary tumor
tissue is not required and the presence of an immune
response to melanoma-associated antigens has been well
documented [1–4]. The investigation of humoral response
provides new perspective to focus on melanoma-associated
antibodies, which are more sensitive and stable to become
diagnostic biomarkersforearly-stagemelanoma. We focused
on glycoproteins, as most of the tumor-associated antigens
are cell surface proteins or released to the extracellular
matrix, where glycosylation is the major type of posttrans-
lational modiﬁcations [5, 6]. Moreover, glycoproteins are
considered to be the linkage between T cells and antigen-
presenting cells to help the orientation of binding, and play
important roles in the generation and loading of antigenic
peptides into MHC class I and MHC class II [5–7].
Using this approach we sought biomarkers that cor-
related with the presence of regional metastases among2 International Journal of Proteomics
melanoma patients. Using dual-lectin aﬃnity chromatog-
raphy and a natural protein microarray-based analysis to
select a subproteome of target glycoproteins which were then
used as baits to proﬁle the antibodies against melanoma-
associated antigens [8]. This signiﬁcantly improved tech-
nology using lectin aﬃn i t yc h r o m a t o g r a p h ya l l o w su st o
concentrate low abundant glycoproteins which are typ-
ically undetectable in whole cell lysate. This approach
led us to the discovery of antibodies to 5 interest-
ing melanoma-associated antigens (75kD glucose-regulated
protein (GRP75), 94kD glucose-regulated protein (GRP94),
acid ceramidase (ASAH1), cathepsin D (CTSD), and lactate
dehydrogenase B (LDHB)) that correlated with the presence
of melanoma within the regional lymph nodes [8]. GRP75,
also known as mortalin, is a transport protein. A member of
theheatshockprotein-70family,italsoinactivatesthetumor
suppressor p53. GRP94, also known as heat shock protein-
90, is a chaperone protein that is involved in the function
and stability of many cell-signaling molecules. ASAH1 is a
catabolic lysosomal enzyme that deacylates ceramide, which
when phosphorylated forms the poten mitogen S1P. CTSD is
a lysosomal acid proteinase which is involved in regulation
of programmed cell death. Lactate dehydrogenase (LDH)
is an enzyme that catalyzes the conversion of lactate to
pyruvate, and serum levels are associated with outcome in
stage IV melanoma. We proposed that these autoantibodies
may form the basis of a serum test that could select patients
for sentinel lymph node biopsy. However, many prognostic
factors show limited utility when used clinically in the
context of known prognostic factors. We therefore sought
to examine the potential clinical utility of these novel serum
markers for predicting regional involvement among patients
with melanoma.
2.MaterialsandMethods
2.1. Patients. In our previous work, we identiﬁed serum au-
toantibodiesthatrecognizedglycoproteinsfromamelanoma
celllineanddistinguishedbetween27node-negativepatients
and 16 node-positive patients. In that work, we subsequently
validated these results using recombinant proteins among
a larger sample set of 79 patients. For this University of
Michigan Institutional Review Board approved project, we
used this latter sample set to examine the clinical utility of
these serum autoantibodies as a predictor of regional node
involvement. Serum samples were obtained from patients
being evaluated at our melanoma multidisciplinary clinic, a
few weeks after the diagnostic biopsy, but 2 to 3 weeks prior
to undergoing wide local excision and lymph node surgery
(SLN biopsy for clinically node-negative patients (n = 71) or
lymph node dissection for clinically node-positive patients
(n = 8)). Blood was allowed to clot at room temperature,
after which the tubes were centrifugated at 2500g for 10
minutes. The serum phase was then harvested and frozen in
1mL aliquots.
2.2. Measurement of Serum Autoantibody Levels. Our initial
discovery (using extracted glycoproteins) and validation
(using recombinant proteins) of these serum autoantibodies
have been previously described [8]. For this study we
used the results obtained with the recombinant proteins.
75kD glucose-regulated protein (GRP75), 94kD glucose-
regulated protein (GRP94), cathepsin D (CTSD), and lactate
dehydrogenase B (LDHB) were purchased from Abcam
(Cambridge, MA, USA). Recombinant acid ceramidase
(ASAH1) was purchased from Abnova (Taiwan). These 5
recombinant proteins were chosen because the amino acid
sequences described in the manufacturers’ instructions are
perfectly matched with the sequences acquired from Swiss-
Prot database. The sequences and the purity of purchased
recombinant proteins were reconﬁrmed by MALDI-QIT
(Shimadzu, CA, USA).
To summarize our previous work, the recombinant
proteins were dissolved in the printing buﬀer (62.5mM Tris-
HCl (pH 6.8), 1%w/v sodium dodecyl sulfate (SDS), 5%w/v
dithiothreitol (DTT), and 1% glycerol in 1x PBS) to reach a
ﬁnal concentration of 100μg/mL, respectively. Each protein
solution was then transferred to a well in a 200μL 96-well
clear printing plate (Bio-rad). The recombinant proteins
from the printing plate were spotted onto nitrocellulose
(Whatman, USA) slides using a noncontact piezoelectric
printer (nanoplotter 2 GeSiM). Each spot contains ﬁve
spotting events of 500pL each so that the total volume
of each protein solution was 2.5nL. Each spot was found
to be ∼450μm in diameter, with the distance between
spots maintained at 600μm. Printed slides were dried on
the printer deck overnight and stored in a refrigerator
desiccated at 4◦C if the slides were not used immediately.
Each recombinant protein was printed in triplicate, and 14
identical blocks were printed on each slide.
The slides were washed three times with 0.1% Tween-
20 in PBS buﬀer (PBST) and then blocked with 1% bovine
serum albumin (Roche) in PBST for 1hr. The blocked slides
were dried by centrifugation and inserted into a SIMplex
(Gentel Bioscience) multiarray device which divides each
slide by 16 wells. The wells separate the neighboring blocks
and prevent cross-contamination. Each serum sample was
diluted 1:200 in probe buﬀer which consisted of 1% BSA,
0.05% Triton X-100, 0.1% brij-30 (Sigma-Aldrich, USA) in
1x PBS. The sample hybridization was totally randomized on
each slide in no speciﬁc order to prevent bias. Each block
was hybridized in 100 microliter of diluted serum for 2hrs
at 4◦C. Then goat-anti-human IgG (H+L) conjugated with
Alexa Fluor 647 (1μg/mL, Invitrogen, Carlsbad, CA) was
applied to each block to bind with the antibodies attached on
the protein array. Anti-human IgG was printed on the array
as positive control and printing buﬀer served as the negative
control. All processed slides were immediately scanned using
an Axon 4000B microarray scanner (Axon Instruments,
Foster City, USA). GenePix Pro 6.0 was used to extract the
numericaldatafromeachspotontheslides.Thebackground
subtractedmedianintensityofeachspotwastakenasasingle
data point. Then the mean intensity of each protein from the
triplicate was used for the further analysis.
2.3. Statistical Analysis. For this study, patient and tumor
characteristics were collectedfor our sample of 79 melanoma






































Figure 1: Humoral response to recombinant 75kD glucose-regulated protein (GRP75), 94kD glucose-regulated protein (GRP94), acid
ceramidase (ASAH1), cathepsin D (CTSD), and lactate dehydrogenase B (LDHB) among healthy volunteers and nonmelanoma skin cancer
patients (H&NSK), node-negative melanoma patients (ENN) and node-positive melanoma patients (ENP).
thickness (Breslow), mitotic rate, presence of ulceration,
and nodal status. For use as a potential clinical test, the
sample distribution of each auto-antibody classiﬁed as over-
or underexpressed, deﬁned as a serum antibody level one
standard deviation increment above the sample mean value.
Association between the levels of the autoantibodies is
summarized by the Spearman rank correlation coeﬃcient
with P values testing for signiﬁcant correlations reported.
The associations between patient, tumor, and antibody
covariates with nodal disease was compared using the two-
sample t-test for continuous covariates and the chi-square or
Fisher’s exact test for categorical covariates. The magnitude
of the association between each serum antibody level and
nodal disease is reported categorically as the odds ratio
and 95% conﬁdence interval for cases with overexpression
versus cases without. Odds ratios and conﬁdence intervals
were reported separately for the univariate associations and
after adjustment for the patient and tumor characteristics
usingstandardlogisticregression.Allstatisticalanalyseswere
conducted using SAS Version 9.2 (SAS Institute, Inc., Cary,
NC, USA) with P values less than 5% considered statistically
signiﬁcant.
3. Results
In the previous work, we used the native proteins extracted
by a dual-lectin column from the melanoma cell line as
bait to detect the presence of autoantibodies in the sera of
melanoma patients, identifying 5 antigens including 75kD
glucose-regulated protein (GRP75), 94kD glucose-regulated
protein (GRP94), acid ceramidase (ASAH1), cathepsin D
(CTSD), and lactate dehydrogenase B (LDHB), and we
investigated the humoral response against the recombinant
proteins using a larger sample set of 79 melanoma patients
(Figure 1). The clinical characteristics of the patient popula-
tion are shown in Table 1 for the total population and strati-
ﬁed by nodal disease status. Of note, one patient with a nega-
tive SLN subsequently recurred in a regional basin, changing
the population from 48 node-negative and 31 node-positive
to 47 node-negative and 32 node-positive patients. Among
the32 node-positive patients, 8 wereclinicallynode-positive,
23wereSLNpositive,and1representedaregionalrecurrence
after false-negative SLN. Each glycoprotein was summarized
by over- (>1SD), standard (±1SD), and underexpression
(<1SD), relative to the sample mean. ASAH1, CTSD, and4 International Journal of Proteomics
Table 1: Patient and tumor characteristics of the study cohort.
Characteristic Total Node negative Node positive P value1
Frequency 79 47 32
Age
Mean (SD) 51.9 (12.6) 51.8 (13.2) 52.0 (12.0) 0.944
Gender
Males: N (%) 38 (48.1) 22 (46.8) 16 (50.0) 0.781
Females: N (%) 41 (51.9) 25 (53.2) 16 (50.0)
Breslow depth
Mean (SD) 2.39 (1.65) 1.94 (1.15) 3.11 (2.04) 0.007
Mitotic rate
Mean (SD) 5.51 (5.72) 4.45 (4.93) 7.04 (6.50) 0.075
Ulceration
Absent: N (%) 24 (30.4) 35 (74.5) 16 (50.0) 0.0592
Present: N (%) 51 (64.6) 11 (23.4) 13 (40.6)
Unknown: N (%) 4 (5.0) 1 (2.1) 3 (9.4)
ASAH1
Mean (SD) 803 (353) 837 (432) 753 (179) 0.238
±1S D :N (%) 68 (86.1) 36 (76.6) 32 (100) 0.008
>1S D :N (%) 8 (10.1) 8 (17.0) 0
<1S D :N (%) 3 (3.8) 3 (6.4) 0
CTSD
Mean (SD) 8664 (4355) 9607 (5014) 7278 (2660) 0.009
±1S D :N (%) 62 (78.5) 33 (70.2) 29 (90.6) 0.039
>1S D :N (%) 12 (15.2) 11 (23.4) 1 (3.1)
<1S D :N (%) 5 (6.3) 3 (6.4) 2 (6.3)
GRP75
Mean (SD) 4087 (2107) 4221 (2367) 3891 (1671) 0.471
±1S D :N (%) 62 (78.5) 36 (76.6) 26 (81.3) 0.913
>1S D :N (%) 13 (16.5) 8 (17.0) 5 (15.6)
<1S D :N (%) 4 (5.1) 3 (6.4) 1 (3.1)
GRP94
Mean (SD) 6798 (3782) 6032 (1840) 7924 (5364) 0.063
±1S D :N (%) 70 (88.6) 47 (100) 23 (71.9) <0.001
>1S D :N (%) 9 (11.4) 0 9 (28.1)
<1S D :N (%) 0 0 0
LDH
Mean (SD) 7863 (4093) 8587 (4933) 6798 (2021) 0.029
±1S D :N (%) 68 (86.1) 37 (78.7) 31 (96.9) 0.056
>1S D :N (%) 10 (12.7) 9 (19.2) 1 (3.1)
<1S D :N (%) 1 (1.3) 1 (2.1) 0
C o m b i n a t i o n :A S A H 1 ,C T S D ,a n dL D H
Overexpressed† 22 (27.9) 20 (42.5) 2 (6.2) <0.001
Normal 57 (72.1) 27 (57.5) 30 (93.8)
1Comparing between node-negative and node-positive groups.
2Unknown group omitted for statistical test.
†Overexpressed deﬁned as >1 SD for ASAH1, CTSD, or LDH.International Journal of Proteomics 5
Table 2: Correlation of antibodies and continuous patient and tumor characteristics: Spearman r, P value.
ASAH1 CTSD GRP75 GRP94 LDH
Age
−0.2317 0.0811 −0.0024 0.0214 0.0539
0.0400 0.4774 0.9836 0.8514 0.6371
Breslow 0.1294 0.0822 0.1975 0.0878 0.1444
0.2686 0.4834 0.0894 0.4539 0.2165
Mitotic rate 0.0630 −0.0253 0.0516 0.0705 0.0485
0.6019 0.8341 0.6693 0.5593 0.6881
Table 3: Univariate associations of glycoproteins with positive nodal status.
Characteristic Odds
ratio 95% CI P value
ASAH1
500 unit increase 0.685 0.332–1.415 0.306
>1 SD versus not 0.123† 0.019
CTSD
500 unit increase 0.928 0.869–0.991 0.026
>1 SD versus not 0.106 0.013–0.864 0.022
GRP75
500 unit increase 0.962 0.860–1.076 0.495
>1 SD versus not 0.903 0.266–3.059 0.999
GRP94
500 unit increase 1.076 1.002–1.156 0.0440
>1 SD versus not 38.4† <0.0001
LDH
500 unit increase 0.931 0.862–1.007 0.0731
>1 SD versus not 0.193† 0.0427
C o m b i n a t i o n :A S A H 1 ,C T S D ,a n dL D H
Any >1 SD versus not 0.173 0.045–0.663 <0.0001
†Continuity correction applied when calculating the estimate of odds ratios due to cell sample sizes ≤1. Conﬁdence interval not reportable in these cases.
LDHB all had signiﬁcant negative associations with the
presence of nodal disease, with overexpression associated
witha lower risk. Higher GRP94levels wereassociated witha
higher risk of nodal disease; however, the level of GRP75 was
not signiﬁcantly associated with nodal status. Correlation
between antibody levels and age, gender, Breslow thickness,
mitotic rate, or ulceration are shown in Table 2. Correlations
included ASAH1 which negatively correlated with patient
age (although the magnitude of the correlation was mild,
r<0.3) and GRP75 which was higher in females than males
(P = 0.03).
The magnitude of the association of the glycoproteins
with nodal disease status is reported in Table 3.E v e na f t e r
adjustment for clinical parameters (age, gender, ulceration,
and Breslow thickness) ASAH1, CTSD, and LDHB remained
signiﬁcantly negatively associated with nodal disease, and
GRP94 positively associated (Table 4). A composite measure
for the overexpression of any of the three proteins shown
to have a negative association with nodal disease (ASAH1,
CTSD, and LDHB) was constructed with 22 (27.9%) of
the total population with composite overexpression. Only
2 (6.2%) of the node-positive patients had composite
overexpression in contrast to 20 (42.5%) node-negative
patients. For the 9 of 32 node-positive patients (28%)
who had overexpression of GRP94, 5 (16%) patients had
clinically involved nodes while the remaining 4 (14%) had
microscopic disease (<2% surface area) in clinically negative
nodes. Table 5 reports the best multivariable model for
nodalpositivity.Overexpressionofanti-ASAH1,anti-LDHB,
or anti-CTSD (decreased risk), the overexpression of anti-
GRP94 (increased risk) and Breslow thickness (increased
risk) signiﬁcantly correlated with the likelihood of regional
metastases. The ROC curve for this model is presented in
Figure 2, with an area under the curve of 0.8690.
4. Discussion
Using dual-lectin aﬃnity chromatography to generate a sub-
proteome of glycoproteins from a melanoma cell line gener-
ated from a metastatic deposit, we discovered 4 antibodies
in the serum of melanoma patients recently diagnosed with
melanoma that were strongly correlated with the presence or
absence of nodal metastases. In this analysis, we demonstrate
that overexpression of these antibodies were independent of6 International Journal of Proteomics
Table 4: Adjusted† associations of glycoproteins with positive nodal status.
Characteristic Odds ratio 95% CI P value
ASAH1
500 unit increase 0.272 0.076–0.979 0.0464
>1S Dv e r s u sn o t Model not estimable
CTSD
500 unit increase 0.867 0.786–0.956 0.0042
>1 SD versus not 0.067 0.006–0.740 0.0275
GRP75
500 unit increase 0.880 0.749–1.034 0.1216
>1 SD versus not 0.644 0.153–2.712 0.5488
GRP94
500 unit increase 1.052 0.976–1.133 0.1871
>1S Dv e r s u sn o t Model not estimable
LDH
500 unit increase 0.890 0.797–0.993 0.0363
>1 SD versus not 0.135 0.015–1.210 0.0736
C o m b i n a t i o n :A S A H 1 ,C T S D ,a n dL D H
Any >1 SD versus none 0.045 0.007–0.309 0.0016
†Adjusted for age, gender, ulceration, and Breslow depth. Due to the very high correlation between mitotic rate and Breslow depth, mitotic rate was omitted
from the model.
Table 5: Best multivariable model explaining positive nodal status.
Characteristic Odds ratio 95% CI P value
Age
1 year increase 0.987 0.935–1.043 0.6468
Gender
Male 1.663 0.426–6.495 0.4645
Female 1.000
Ulceration
Present 2.046 0.359–11.662 0.4201
Absent 1.000
Breslow
1mm increase 2.178 1.104–4.298 0.0248





Overexpressed 1.223 1.041–1.436 0.0141
Not overexpressed 1.000
other known prognostic factors in melanoma, and on mul-
tivariate analysis maintained highly signiﬁcant, independent
prognostic value. These results demonstrate the potential of
these 4 autoantibodies as a serum test for the purpose of
selecting clinically node-negative patients for SLN biopsy.
Elevation(deﬁnedas>1SDabovethemean)ofanti-ASAH1,
anti-CTSD, or anti-LDHB was highly signiﬁcantly associated
with being SLN negative, with an odds ratio of 0.05 (0.01–
0.31, P = 0.002) after adjusting for age, gender, ulceration,
mitotic rate, and Breslow thickness. Elevation of one of these
threeantibodieswasnotuncommon;amongthe70clinically
node-negative patients in this study, 22 patients (33%) had
elevation of one of these antibodies. If it were validated that
patients with elevation of one of these antibodies had a very
low risk of SLN metastases, then potentially these patients
couldbetreatedbywideexcisionalone,reducingthecostand
morbidity of melanoma treatment. In contrast, elevation of
anti-GRP94 was associated with an increased risk of regional
metastases, and was elevated in both patients with clinically
evident disease (5 of 8 patients) and microscopic diseaseInternational Journal of Proteomics 7

















ROC curve for model
Area under the curve = 0.869
1-speciﬁcity
Figure 2: Receiver operating characteristic (ROC) curve for our
bestmultivariable model fornodal positivity incorporating increas-
ing Breslow thickness (increased risk), autoantibody response to
GRP94 (increased risk), and autoantibody response to ASAH1,
LDHB, or CTSD (decreased risk).
(4 of 23 patients). While detection of serum anti-GRP94
levels would be less useful clinically, it could potentially
identify some patients with thin melanoma for whom SLN
might otherwise be omitted.
A bigger question is the role these proteins may play
in the development and progrsion of melanoma. Beyond
thedevelopmentofserum-baseddiagnostictests,proteomics
may identify targets for therapeutic intervention. Indeed, 3
of the 4 proteins have strong associations with melanoma
progression and prognosis. Lactate dehydrogenase (LDH)
is an enzyme that catalyzes the conversion of lactate to
pyruvate, and serum levels of LDH are strongly associated
with melanoma prognosis. Serum LDH levels strongly
correlate with outcome among stage IV patients and serum
LDH measurements are part of the American Joint Cancer
Commission (AJCC) staging system for melanoma [9–13].
However, serum LDH levels are rarely elevated and of no
clinical utility in nonmetastatic melanoma [14–16]. Cathep-
sin D (CTSD) is a lysosomal acid proteinase which degrades
proteins, peptides, and peptide precursors. In addition, it
appearstobeinvolvedinotherbiologicalprocessesincluding
regulation of programmed cell death, tissue remodeling and
renewal, activation of proteolytic enzymes, and ﬁbrinolysis
[17]. Many tumors have altered processing, secretion, and
activity levels of CTSD, and they are often associated with
aggressive behavior, stimulating tumor cell proliferation,
invasion, and metastases [17, 18]. Immunohistochemical
studies have shown that CTSD is markedly expressed in
melanoma cell lines and tissue biopsies from primary and
metastaticmelanoma,andthesecorrelatewithpooroutcome
[19–24]. As with LDH, measuring plasma levels of CTSD
was not of clinical value for identifying patients at risk of
recurrence [17, 25]. As we can detect very low levels of
antibodies in the serum, measuring antibody levels may
be more sensitive than measuring protein levels, allowing
transition of known serum markers from utility in stage IV
disease only to the setting of early-stage disease. Prior to this
publication,thethirdprotein,acidceramidase(ASAH1),had
not been strongly associated with melanoma progression,
but has been associated with cancers of the breast, prostate,
andthyroid[26–29].ASAH1isacatabolic lysosomalenzyme
that deacylates ceramide and yields sphingosine, which when
phosphorylated, forms the potent mitogen S1P. The cellular
levels of ceramide, sphingosine, and S1P are integral in
determining cell survival and growth [30–32]. Targeting this
pathway holds promise for anticancer therapies [32–34].
In the case of these three proteins, expression of the pro-
teins is associated with advanced stage, but the presence
of antibodies to these proteins is associated with lower
stage. This highlights one drawback to antibody-array-based
proteomics—the presence of the antibody may be due to
increasedexposureoftheproteins(overexpression),immune
recognition of protein alteration, or the antibodies may be
functionally blocking critical pathways. In the case of these
three proteins/antibodies, it remains unclear whether this
represents speciﬁc functional inhibition by the antibodies,
or increased progression in the face of decreased immune
recognition of overexpressed proteins (disease advancement
in the face of decreased immune surveillance). As these
proteins are identiﬁed, further analysis of their role in
melanoma progression, and their posttranslational structure
is necessary.
In contrast to these three proteins, for which the
detection of autoantibodies was a favorable prognostic sign,
the presence of autoantibodies to GRP94, or heat shock
protein-90 (HSP90), was associated with an increased risk
of regional metastases. Although this protein is highly
conserved (and should not trigger a signiﬁcant immune
response), our primary data and validation studies using
the recombinant proteins demonstrate the presence of anti-
GRP94 antibodies in the serum of nearly between 1/4a n d
1/3 of node-positive patients. HSP90 is a chaperone protein
thatiscruciallyinvolvedinthefunctionandstabilityofmany
oncogene products and cell-signaling molecules, including
CRAF, ERB-B2, BCR-ABL, CDK4, CDK6, AKT, mutated
p53, MEK, VEGFR, and importantly to melanoma mutated
(but not wildtype) BRAF. HSP90 protects these proteins
from deterioration caused by environmental stress, which
includes cancer therapy. Expression of HSP90 is elevated
in melanoma, correlates with increasing Breslow thickness,
and is associated with advanced disease [35]. Because HSP90
chaperones so many proteins implicated in carcinogenesis,
inhibiting HSP90 could inhibit several pathways at once,
HSP90 inhibitors are presently in clinical trial in metastatic
melanoma. While our data suggest that autoantibodies
do little to inhibit HSP90 functionally, their presence as
a response to overexpression is clearly related to melanoma
progression.8 International Journal of Proteomics
In conclusion, the creation of a glycoprotein microarray
to screen melanoma patient serum samples for autoanti-
bodies yielded four autoantibodies that show promise in
predicting regional metastases, and could potentially form
the basis of a blood test to select clinically node-negative
patients for SLN biopsy. If validated, this test could greatly
minimize the cost and morbidity associated with the surgical
treatment of melanoma, as well as identify patients with
thin melanomas who should undergo the procedure. In
addition, glycoproteins recognized by these antibodies may
have important roles in the development and progression
of melanoma and may serve as targets for intervention. On
a broader scale, this approach could be used to identify
additional serum autoantibodies that can identify patients at
high risk of distant metastases and those unlikely to respond
to treatment, allowing a more tailored use of adjuvant
therapies.
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